Chlamydia Screening (CHL)

The percentage of persons 16–24 years of age who were recommended for routine chlamydia screening, were identified as sexually active and had at least one test for chlamydia during the measurement period.

Why It Matters

Chlamydia trachomatis is among the most common sexually transmitted diseases in the United States. Chlamydia screening is essential because most cisgender women and persons assigned female at birth who have the condition do not experience symptoms. The main objective of chlamydia screening is to prevent pelvic inflammatory disease, infertility and ectopic pregnancy, all of which have very high rates of occurrence among cisgender women and persons assigned female at birth with untreated chlamydia infection 1. The specifications for this measure are consistent with USPSTF clinical guidelines and guidelines for care among transgender and gender-diverse populations 2 3 4.

Historical Results – National Averages

Get Access to the Historical Results

By completing the form below, you’ll gain free access to national performance data.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

References

  1. Centers for Disease Control and Prevention. 2019. “Sexually Transmitted Disease Surveillance 2018.” Atlanta: U.S. Department of Health and Human Services. https://doi.org/10.15620/cdc.79370.
  2. U.S. Preventive Services Task Force. September 14, 2021. “Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement,” JAMA 326, no. 10: 949–56, https://doi.org/10.1001/jama.2021.14081.
  3. Thompson, J. March 2021. “Medical Care of Trans and Gender Diverse Adults” (Boston: Fenway Health).
  4. E. Coleman et al., “Standards of Care for the Health of Transgender and Gender Diverse People, Version 8,” International Journal of Transgender Health 23, no. sup1 (August 19, 2022): S1–259. https://doi.org/10.1080/26895269.2022.2100644.

  • Save
  • Email
  • Print